1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Healios K.K.

Healios K.K.

HLOSF
Healios K.K.US flagOther OTC
1.80
USD
- -
- -
193.79MMarket Cap
Healios K.K.
HLOSF
(Other OTC)

Recent

price

1.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.31
2.62
1.91
0.6
- -
1.78
0.53
0.78
1.32
1.78
6.33
0.97
6.43
Revenue per Share
-14.17
-25.6
-84.33
-39.72
-103.52
-95.86
-107.2
-93.36
-76.01
-56.22
-47.86
-20.59
-66.33
Basic EPS, GAAP
- -
-6.13
-95.18
-40.99
-106.52
-99.45
-82.81
-102.47
-71.51
-41.91
-24
-30.95
-37.67
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
32.72
106.64
14.02
106.32
68.59
0.12
53.93
66.3
32.06
49.16
21.55
33.17
36.27
Book Value per Share
52.43
229.18
130.04
361.35
211.87
167.46
75.94
89.35
5.73
-3.94
-26.42
4.49
-14.28
Tangible Book Value per Share
34
37
41
45
49
50
51
53
68
68
88
108
81
Basic Weighted Avg Shares
280
98
78
27
- -
89
27
41
90
121
560
104
522
Sales/Revenue/Turnover
-202.96
-1,080.22
-4,517.6
-8,696.3
- -
-4,826.97
-15,496.3
-13,131.71
-5,754.44
-2,792.56
-507.5
-3,211.54
-604.79
Operating Margin (%)
- -
128
143
74
51
141
229
262
386
224
297
275
149
Depreciation Expense
-477
-958
-3,434
-1,776
-5,097
-4,806
-5,512
-4,910
-5,169
-3,823
-4,235
-2,217
-5,389
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-170.45
-975.99
-4,422.4
-6,577.78
- -
-5,400
-20,414.81
-11,975.61
-5,743.33
-3,159.5
-756.25
-2,131.73
-1,032.38
Profit Margin (%)
1,588
8,245
7,302
17,988
11,168
17,413
12,321
10,387
4,654
2,514
925
3,217
2,748
Working Capital
- -
- -
2,371
2,199
2,661
10,158
11,281
7,096
4,011
450
2,546
2,025
2,049
LT Debt
2,665
9,377
5,994
16,163
14,378
12,343
7,851
8,645
4,382
3,868
2,084
4,899
3,265
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-37.63
-150.54
-66.7
-125.37
-284.13
-396.69
-156.87
-182.42
-138.44
-161.33
-80.93
-149.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
4,082
4,066
4,050
LT Borrowings
450
450
2,049
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
90
90
Market Capitalization
- -
10,004
15,817

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
7,683
9,130
9,860
Cash, Cash Equivalents & STI
6,722
8,385
8,894
Accounts Receivable, Net
324
333
563
Inventories
- -
- -
- -
Total Current Liabilities
5,169
6,803
7,112
Payables & Accruals
- -
- -
- -
ST Debt
4,082
4,066
4,050
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11%
7.61%
135.08%
Free Cash Flow
170.99%
1.37%
56.92%
Net Income, GAAP
33.75%
-13.71%
-47.65%
Sales/Revenue/Turnover
- -
97.44%
-81.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10
498
- -
- -
560
2025
- -
- -
- -
- -
104
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-29.05
-5.92
- -
- -
-47.86
2025
- -
- -
- -
- -
-20.59
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Oncoinvent ASA (0RU5.L)
Regeneus Ltd (RGS.AX)
Nasus Pharma Ltd. (NSRX)
Addex Therapeutics Ltd (0QNV.L)
Ondine Biomedical Inc. (OBI.L)
Silverback Therapeutics, Inc. (SBTX)
Business
Healios K.K. (TSE: 4593) develops, manufactures and commercializes cell and gene therapies focused on regenerative medicine products targeting unmet needs in acute respiratory distress syndrome (ARDS), ischemic stroke, trauma and solid tumors; its lead asset HLCM051 (MultiStem), a bone marrow-derived somatic stem cell product licensed globally following the April 2024 acquisition of substantially all assets from bankrupt Athersys Inc., advances in late-stage trials including Phase 3 confirmatory studies planned in the US for ARDS with conditional time-limited approval targeted in Japan by 2025, Phase 2/3 data integration for ischemic stroke and US Department of Defense-funded Phase 2 for trauma; the company pursues immuno-oncology via gene-edited iPSC-derived natural killer (eNK) cells such as HLCN061 for solid tumors including gastric cancer, mesothelioma, lung cancer and hepatocellular carcinoma with pre-IND activities underway and first clinical trials planned for 2025, alongside universal donor cells (UDC), iPSC-derived retinal pigment epithelial (RPE) cells for age-related macular degeneration and RPE tear in partnership with Sumitomo Pharma Co. Ltd. via joint venture Sighregen Co. Ltd., and medical materials including cultured supernatants for beauty clinics and cosmetics; additional offerings encompass secure integrated freezer units (SIFU) for cell therapy storage and 3D bioreactor technology for scalable production. Founded in 2011 and headquartered in Tokyo with a research institute in Kobe, Healios operates primarily in Japan, the US, Europe and Asia through subsidiaries including ProcellCure Inc. for ARDS development, eNK Therapeutics Inc., Healios NA Inc. and fund vehicles like Saisei Bioventures L.P. Recent developments include a June 2024 basic business alliance and 1.6 billion yen bond purchase with Alfresa Corp. for product distribution, an April 2024 joint research agreement with AND Medical Group yielding upfront payments and projected several billion yen in supernatant sales by FY2026, a non-exclusive license to Astellas Pharma subsidiary Astellas Institute for Regenerative Medicine for RPE cell production patents excluding Japan, a January 2025 master collaboration with Akatsuki Therapeutics Inc. for eNK cell R&D, and selection for Japanese government grants including 7 billion yen METI funding and AMED support for eNK industrialization.